oral cannabinoid
dronabinol
dronabinolLoading study record…
Loading study record…
Photorefractive Keratectomy (PRK) is a commonly performed corneal refractive surgery but has significant post-operative pain. Pain medications after PRK are typically opioid-acetaminophen combinations. Alternatives to opioid medication are worth consideration. Patients will receive PRK in each eye sequentially, using the cannabinoid or codeine/acetaminophen for one eye and the other treatment for the fellow eye two weeks later.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2025-08-07
What this record can show
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
Registry facts
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
dronabinol
dronabinol10 tablets of acetaminophen-codeine combination (300-30mg) without refills.
Source-reported results
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
The Wong-Baker Faces Pain Rating Scale is a pain scale that was developed by Donna Wong and Connie Baker. The scale shows a series of faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable"
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Cannabidiol | 16 | 1.33 | 0.95 |
| Tylenol T3 | 19 | 1.27 | 0.89 |
The Wong-Baker Faces Pain Rating Scale is a pain scale that was developed by Donna Wong and Connie Baker. The scale shows a series of faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable"
| Group | N | Value | Spread / interval |
|---|
Eligibility
primary outcomes
Time frame: 1 week after first surgery
The Wong-Baker Faces Pain Rating Scale is a pain scale that was developed by Donna Wong and Connie Baker. The scale shows a series of faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable"
Time frame: 1 week after second surgery
The Wong-Baker Faces Pain Rating Scale is a pain scale that was developed by Donna Wong and Connie Baker. The scale shows a series of faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable"
secondary outcomes
Time frame: 3 months after first surgery
Uncorrected visual acuity as measured by Snellen Chart
Time frame: 3 month
An online questionnaire derived from the Patient-Reported Outcomes With LASIK (PROWL) will be given to patients after PRK at 3 months. It ranges from 0-100, where 100 indicates best possible vision and satisfaction, while 0 indicates worst possible vision and satisfaction.
Time frame: 3 months
The QIRC measures quality of life associated with vision and eyewear problems, measured at 3 months. It ranges from 0-100, where 0 indicates best possible vision and quality of life and 100 indicates worst possible vision and quality of life.
Time frame: 3 months
An online questionnaire derived from the Ocular Surface Disease Index (OSDI) at 3 months. It ranges from 0-48, where 0 indicates no eye discomfort and 48 indicates constant, debilitating, worst-possible eye discomfort or pain.
Time frame: 3 months after second surgery
Uncorrected visual acuity as measured by Snellen Chart
Publications
No exact PMID-linked public article is currently readable locally.
| Cannabidiol | 19 | 1.46 | 0.82 |
| Tylenol T3 | 16 | 1.79 | 1.12 |
Uncorrected visual acuity as measured by Snellen Chart
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Cannabidiol | 16 | -0.123 | 0.119 |
| Tylenol T3 | 19 | -0.054 | 0.169 |
An online questionnaire derived from the Patient-Reported Outcomes With LASIK (PROWL) will be given to patients after PRK at 3 months. It ranges from 0-100, where 100 indicates best possible vision and satisfaction, while 0 indicates worst possible vision and satisfaction.
Population: Surveys assess overall quality of life which cannot be specifically attributed to a single eye since vision is binocular. For example, having excellent vision in one eye and poor vision in the other can be more disturbing than having poor vision in both eyes or cause patients to suffer from double vision. Because all survey measurements are implied to be binocular at 3 months after both surgeries are done, results are displayed by group instead of intervention. There is no separate measurement.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Group 1 | 16 | 58.0 | 20.1 |
| Group 2 | 19 | 60.9 | 18.3 |
| Group 1 | 16 | 81.6 | 9.0 |
| Group 2 | 19 | 85.6 | 6.9 |
The QIRC measures quality of life associated with vision and eyewear problems, measured at 3 months. It ranges from 0-100, where 0 indicates best possible vision and quality of life and 100 indicates worst possible vision and quality of life.
Population: Surveys assess overall quality of life which cannot be specifically attributed to a single eye since vision is binocular. For example, having excellent vision in one eye and poor vision in the other can be more disturbing than having poor vision in both eyes or cause patients to suffer from double vision. Because all survey measurements are implied to be binocular at 3 months after both surgeries are done, results are displayed by group instead of intervention. There is no separate measurement.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Group 1 | 16 | 37.7 | 6.2 |
| Group 2 | 19 | 37.6 | 10.6 |
| Group 1 | 16 | 19.2 | 6.0 |
| Group 2 | 19 | 26.4 | 6.3 |
An online questionnaire derived from the Ocular Surface Disease Index (OSDI) at 3 months. It ranges from 0-48, where 0 indicates no eye discomfort and 48 indicates constant, debilitating, worst-possible eye discomfort or pain.
Population: Surveys assess overall quality of life which cannot be specifically attributed to a single eye since vision is binocular. For example, having excellent vision in one eye and poor vision in the other can be more disturbing than having poor vision in both eyes or cause patients to suffer from double vision. Because all survey measurements are implied to be binocular at 3 months after both surgeries are done, results are displayed by group instead of intervention. There is no separate measurement.
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Group 1 | 16 | 4.9 | 5.7 |
| Group 2 | 19 | 4.8 | 5.4 |
| Group 1 | 16 | 4.9 | 4.8 |
| Group 2 | 19 | 3.9 | 4.0 |
Uncorrected visual acuity as measured by Snellen Chart
| Group | N | Value | Spread / interval |
|---|---|---|---|
| Cannabidiol | 19 | -0.051 | 0.16 |
| Tylenol T3 | 16 | -0.075 | 0.121 |
Any patient who could not undergo surgery due to contraindications such as thin cornea, irregular astigmatism, or inability to lay flat were excluded. Patients who could not undergo sequential eye surgery due to scheduling constraints could not enroll in the study.
| Milestone | Group 1 | Group 2 |
|---|---|---|
| STARTED | 16 | 19 |
| COMPLETED | 16 | 19 |
| NOT COMPLETED | 0 | 0 |
| Milestone | Group 1 | Group 2 |
|---|---|---|
| STARTED | 16 | 19 |
| COMPLETED | 16 | 19 |
| NOT COMPLETED | 0 | 0 |
| Milestone | Group 1 | Group 2 |
|---|---|---|
| STARTED | 16 | 19 |
| COMPLETED | 16 | 19 |
| NOT COMPLETED | 0 | 0 |
| Milestone | Group 1 | Group 2 |
|---|---|---|
| STARTED | 16 | 19 |
| COMPLETED | 16 | 19 |
| NOT COMPLETED | 0 | 0 |